Skip to main content
Midas Edge

Elicio Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

ELTX$1.65+8.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

Page
Forward-Looking Statements2
Part I
Item 1. Business4
Item 1A. Risk Factors34
Item 1B. Unresolved Staff Comments90
Item 1C. Cybersecurity90
Item 2. Properties91
Item 3. Legal Proceedings91
Item 4. Mine Safety Disclosures91
Part II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities92
Item 6. [Reserved]92
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations92
Item 7A. Quantitative and Qualitative Disclosures about Market Risk100
Item 8. Financial Statements and Supplementary Data101
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure130
Item 9A. Controls and Procedures130
Item 9B. Other Information131
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections131
Part III
Item 10. Directors, Executive Officers and Corporate Governance132
Item 11. Executive Compensation132
Item 12. Security Ownership of Beneficial Owners and Management and Related Stockholder Matters132
Item 13. Certain Relationships and Related Transactions, and Director Independence132
Item 14. Principal Accountant Fees132
Part IV
Item 15. Exhibits and Financial Statement Schedules133
SIGNATURES136
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.